Chiesi USA Inc – Strategic SWOT Analysis Review provides a comprehensive insight into the company’s history, corporate strategy, business structure and operations. The report contains a detailed SWOT analysis, information on the company’s key employees, key competitors and major products and services.
This up-to-the-minute company report will help you to formulate strategies to drive your business by enabling you to understand your partners, customers and competitors better.

Scope

- Business description – A detailed description of the company’s operations and business divisions.
- Corporate strategy – GlobalData’s summarization of the company’s business strategy.
- SWOT analysis – A detailed analysis of the company’s strengths, weakness, opportunities and threats.
- Company history – Progression of key events associated with the company.
- Major products and services – A list of major products, services and brands of the company.
- Key competitors – A list of key competitors to the company.
- Key employees – A list of the key executives of the company.
- Executive biographies – A brief summary of the executives’ employment history.
- Key operational heads – A list of personnel heading key departments/functions.
- Important locations and subsidiaries – A list of key locations and subsidiaries of the company, including contact details.

Highlights

Chiesi USA Inc (Chiesi USA), a subsidiary of Chiesi Farmaceutici SpA, is a specialty pharmaceutical company. It researches, develops, produces and commercializes therapies in cardiovascular, respiratory, neonatology, rare disease and special care therapeutics. The company’s product portfolio comprises Cardene I.V. (nicardipine hydrochloride); Curosurf (poractant alfa); Zyflo (zileuton), Bethkis (tobramycin), Argatroban injection (Argatroban) and Retavase (reteplase). It offers products to retail pharmacy chains, wholesalers, group purchasing organizations, hospital systems and specialty pharmacies.Chiesi USA is headquartered in Cary, North Carolina, the US.

Chiesi USA Inc Key Recent Developments

Dec 08,2020: Chiesi USA appoints Jon Zwinski as General Manager and Chief Executive Officer
Nov 11,2020: Chiesi USA earns fourth consecutive Corporate Philanthropy Award by Triangle Business Journal
Jul 16,2020: Chiesi publishes its annual report: Group generates almost €2 billion and obtains B Corp certification in 2019
Mar 31,2020: Chiesi USA increases support measures for employees, patients and community partners in response to COVID-19 pandemic
Feb 27,2020: Chiesi Global Rare Diseases recognizes Rare Disease Day and highlights plans to expand focus on Patient Advocacy in 2020

Reasons to Buy

- Gain key insights into the company for academic or business research purposes. Key elements such as SWOT analysis and corporate strategy are incorporated in the profile to assist your academic or business research needs.
- Identify potential customers and suppliers with this report’s analysis of the company’s business structure, operations, major products and services and business strategy.
- Understand and respond to your competitors’ business structure and strategies with GlobalData’s detailed SWOT analysis. In this, the company’s core strengths, weaknesses, opportunities and threats are analyzed, providing you with an up to date objective view of the company.
- Examine potential investment and acquisition targets with this report’s detailed insight into the company’s strategic, business and operational performance.

Note: Some sections may be missing if data is unavailable for the company.